Tereza Martinu

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2028655/publications.pdf Version: 2024-02-01



TEDEZA MADTINII

#	Article	IF	CITATIONS
1	Diffusing capacity of the lung for carbon monoxide: association with long-term outcomes after lung transplantation in a 20-year longitudinal study. European Respiratory Journal, 2022, 59, 2003639.	6.7	3
2	<i>Ex vivo</i> delivery of regulatory T-cells for control of alloimmune priming in the donor lung. European Respiratory Journal, 2022, 59, 2100798.	6.7	9
3	Outcomes of lung transplantation from organ donation after medical assistance in dying: First North American experience. American Journal of Transplantation, 2022, 22, 1637-1645.	4.7	6
4	Interferon-stimulated and metallothionein-expressing macrophages are associated with acute and chronic allograft dysfunction after lung transplantation. Journal of Heart and Lung Transplantation, 2022, 41, 1556-1569.	0.6	8
5	Eosinophils in transbronchial biopsies: a predictor of chronic lung allograft dysfunction and reduced survival after lung transplantation — a retrospective singleâ€center cohort study. Transplant International, 2021, 34, 62-75.	1.6	15
6	Association between renin-angiotensin system and chronic lung allograft dysfunction. European Respiratory Journal, 2021, 58, 2002975.	6.7	6
7	Correlation between BAL CXCR3 chemokines and lung allograft histopathologies: A multicenter study. American Journal of Transplantation, 2021, 21, 3401-3410.	4.7	5
8	Long-term outcomes of sensitized lung transplant recipients after peri-operative desensitization. American Journal of Transplantation, 2021, 21, 3444-3448.	4.7	16
9	Engineered mesenchymal stromal cell therapy during human lung exÂvivo lung perfusion is compromised by acidic lung microenvironment. Molecular Therapy - Methods and Clinical Development, 2021, 23, 184-197.	4.1	13
10	Recipient bone marrow-derived IL-17 receptor A-positive cells drive allograft fibrosis in a mouse intrapulmonary tracheal transplantation model. Transplant Immunology, 2021, 69, 101467.	1.2	2
11	The impact of first untreated subclinical minimal acute rejection on risk for chronic lung allograft dysfunction or death after lung transplantation. American Journal of Transplantation, 2020, 20, 241-249.	4.7	29
12	DNase to the Rescue! Clearing Mitochondrial DNA May Have NET Benefits in Lung Transplantation. American Journal of Respiratory Cell and Molecular Biology, 2020, 62, 277-278.	2.9	1
13	Extracellular Matrix Injury of Kidney Allografts in Antibody-Mediated Rejection: A Proteomics Study. Journal of the American Society of Nephrology: JASN, 2020, 31, 2705-2724.	6.1	29
14	Risk assessment of chronic lung allograft dysfunction phenotypes: Validation and proposed refinement of the 2019 International Society for Heart and Lung Transplantation classification system. Journal of Heart and Lung Transplantation, 2020, 39, 761-770.	0.6	45
15	Mesenchymal stromal cell therapy during ex vivo lung perfusion ameliorates ischemia-reperfusion injury in lung transplantation. Journal of Heart and Lung Transplantation, 2019, 38, 1214-1223.	0.6	56
16	A B cell–dependent pathway drives chronic lung allograft rejection after ischemia–reperfusion injury in mice. American Journal of Transplantation, 2019, 19, 3377-3389.	4.7	29
17	Lentiviral interleukin-10 gene therapy: Safety and questions. Journal of Thoracic and Cardiovascular Surgery, 2019, 157, 818-819.	0.8	1
18	Chronic lung allograft dysfunction: Definition, diagnostic criteria, and approaches to treatment―A consensus report from the Pulmonary Council of the ISHLT. Journal of Heart and Lung Transplantation, 2019, 38, 493-503.	0.6	518

Tereza Martinu

#	Article	IF	CITATIONS
19	Cytokine profile in lung transplant recipients with <i>Aspergillus</i> spp colonization. Transplant Infectious Disease, 2019, 21, e13060.	1.7	3
20	Life-threatening bronchiolitis related to electronic cigarette use in a Canadian youth. Cmaj, 2019, 191, E1321-E1331.	2.0	83
21	Spectrum of chronic lung allograft pathology in a mouse minor-mismatched orthotopic lung transplant model. American Journal of Transplantation, 2019, 19, 247-258.	4.7	17
22	Effects of Warm Versus Cold Ischemic Donor Lung Preservation on the Underlying Mechanisms of Injuries During Ischemia and Reperfusion. Transplantation, 2018, 102, 760-768.	1.0	17
23	Acute Cellular Rejection: Is It Still Relevant?. Seminars in Respiratory and Critical Care Medicine, 2018, 39, 181-198.	2.1	15
24	Donor bronchial wash bile acid and suitability of donor lungs for transplantation. Journal of Heart and Lung Transplantation, 2018, 37, 304-306.	0.6	4
25	Chronic Airway Fibrosis in Orthotopic Mouse Lung Transplantation Models—An Experimental Reappraisal. Transplantation, 2018, 102, e49-e58.	1.0	20
26	A novel combined exÂvivo and inÂvivo lentiviral interleukin-10 gene delivery strategy at the time of transplantation decreases chronic lung allograft rejection in mice. Journal of Thoracic and Cardiovascular Surgery, 2018, 156, 1305-1315.	0.8	21
27	Comprehensive outcomes after lung retransplantation: A singleâ€center review. Clinical Transplantation, 2018, 32, e13281.	1.6	25
28	Pentraxin 3 deficiency enhances features of chronic rejection in a mouse orthotopic lung transplantation model. Oncotarget, 2018, 9, 8489-8501.	1.8	9
29	Lung Lavage and Surfactant Replacement During Ex Vivo Lung Perfusion for Treatment of Gastric Acid Aspiration–Induced Donor Lung Injury. Journal of Heart and Lung Transplantation, 2017, 36, 577-585.	0.6	66
30	Introduction to the 59th Annual Thomas L. Petty Aspen Lung Conference. Lung Transplantation: Opportunities for Repair and Regeneration. Annals of the American Thoracic Society, 2017, 14, S209-S209.	3.2	0
31	<i>De Novo</i> DQ Donor-Specific Antibodies Are Associated with Chronic Lung Allograft Dysfunction after Lung Transplantation. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 596-606.	5.6	138
32	Halofuginone treatment reduces interleukin-17A and ameliorates features of chronic lung allograft dysfunction in a mouse orthotopic lung transplant model. Journal of Heart and Lung Transplantation, 2016, 35, 518-527.	0.6	26
33	Impaired CD8+ T cell immunity after allogeneic bone marrow transplantation leads to persistent and severe respiratory viral infection. Transplant Immunology, 2015, 32, 51-60.	1.2	9
34	Neurobehavioral Functioning and Survival Following Lung Transplantation. Chest, 2014, 145, 604-611.	0.8	61
35	Allogeneic Splenocyte Transfer and Lipopolysaccharide Inhalations Induce Differential T Cell Expansion and Lung Injury: A Novel Model of Pulmonary Graft-versus-Host Disease. PLoS ONE, 2014, 9, e97951.	2.5	6
36	Innate immune activation potentiates alloimmune lung disease independent of chemokine (C-X-C motif) receptor 3. Journal of Heart and Lung Transplantation, 2011, 30, 717-725.	0.6	17

Tereza Martinu

#	Article	IF	CITATIONS
37	Acute Allograft Rejection: Cellular and Humoral Processes. Clinics in Chest Medicine, 2011, 32, 295-310.	2.1	69
38	Acute Cellular Rejection and Humoral Sensitization in Lung Transplant Recipients. Seminars in Respiratory and Critical Care Medicine, 2010, 31, 179-188.	2.1	45
39	Acute Rejection and Humoral Sensitization in Lung Transplant Recipients. Proceedings of the American Thoracic Society, 2009, 6, 54-65.	3.5	145
40	Pathologic Correlates of Bronchiolitis Obliterans Syndrome in Pulmonary Retransplant Recipients. Chest, 2006, 129, 1016-1023.	0.8	75
41	A 50-Year-Old Woman With Bilateral Vocal Cord Paralysis and Hilar Mass. Chest, 2005, 128, 1028-1031.	0.8	5
42	Plasma <scp>CXCL9</scp> and <scp>CXCL10</scp> at Allograft Injury Predicts Chronic Lung Allograft Dysfunction. American Journal of Transplantation, 0, , .	4.7	7